<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885882</url>
  </required_header>
  <id_info>
    <org_study_id>E0302-J064-003</org_study_id>
    <nct_id>NCT03885882</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants</brief_title>
  <official_title>An Open-Label, Randomized, Single Dose Study to Evaluate the Pharmacokinetics of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the PK and safety after administration of three types of E0302 SR tablets (SR1,
      SR2, SR3) and E0302 IR tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2019</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort 1 and Cohort 2 will receive treatment as parallel assignment. Cohort 3 will receive treatment in cross-over manner.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for E0302 SR1, SR2, SR3 and IR</measure>
    <time_frame>Cohort 1 and 2 Day 1: 0-72 hours post dose; Cohort 3 Day 1 or 7: 0-72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t): Area Under the Concentration-Time Curve From Zero Time to Time of Last Quantifiable Concentration</measure>
    <time_frame>Cohort 1 and 2 Day 1: 0-72 hours post dose, Cohort 3 Day 1 or 7: 0-72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0 - infinity): Area Under the Concentration-Time Curve From Zero Time Extrapolated to Infinite Time</measure>
    <time_frame>Cohort 1 and 2 Day 1: 0-72 hours post dose, Cohort 3 Day 1 or 7: 0-72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs)</measure>
    <time_frame>Cohort 1 and Cohort 2: Up to 12 days, Cohort 3: Up to 18 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Clinical Laboratory Values</measure>
    <time_frame>Cohort 1 and Cohort 2: Up to Day 4, Cohort 3: Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Sign Values</measure>
    <time_frame>Cohort 1 and Cohort 2: Up to Day 2, Cohort 3: Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal 12-lead Electrocardiogram Values</measure>
    <time_frame>Cohort 1 and Cohort 2: Up to Day 12, Cohort 3: Up to Day 18</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cohort 1: E0302 Sustained Release (SR1) 1500 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: E0302 Sustained Release (SR3) 1500 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E0302 SR1</intervention_name>
    <description>E0302 SR1, oral tablet.</description>
    <arm_group_label>Cohort 1: E0302 Sustained Release (SR1) 1500 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E0302 SR3</intervention_name>
    <description>E0302 SR3, oral tablet.</description>
    <arm_group_label>Cohort 2: E0302 Sustained Release (SR3) 1500 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E0302 SR2</intervention_name>
    <description>E0302 SR2, oral tablet.</description>
    <arm_group_label>Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg</arm_group_label>
    <arm_group_label>Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E0302 IR</intervention_name>
    <description>E0302 IR, oral tablet.</description>
    <arm_group_label>Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg</arm_group_label>
    <arm_group_label>Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following criteria to be included in this study:

        1. Body mass index (BMI) of 18 to 30 kilogram per meter square [kg/m2], inclusive at
        Screening

        Exclusion Criteria:

        Participants who meet any of the following criteria will be excluded from this study:

          1. History of drug or alcohol dependency or abuse within the 2 years before Screening, or
             those who have a positive urine drug test or breath alcohol test at Screening or
             Baseline

          2. Subjects who contravene the restrictions on concomitant medications, food and
             beverages

          3. Currently enrolled in another clinical study or used any investigational drug or
             device within 3 months preceding informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E0302</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>E0302 SR Tablet</keyword>
  <keyword>E0302 IR Tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

